Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

被引：0
|
作者：
Denise A. Yardley
Adam Brufsky
Robert E. Coleman
Pierfranco F. Conte
Javier Cortes
Stefan Glück
Jean-Mark A. Nabholtz
Joyce O’Shaughnessy
Robert M. Beck
Amy Ko
Markus F. Renschler
Debora Barton
Nadia Harbeck
机构：
[1] Sarah Cannon Research Institute and the Tennessee Oncology,Department of Surgery, Oncology and Gastroenterology
[2] PLLC,undefined
[3] University of Pittsburgh Medical Center,undefined
[4] Weston Park Hospital,undefined
[5] Sheffield Cancer Research Center,undefined
[6] University of Padova,undefined
[7] Padova,undefined
[8] and Istituto Oncologico Veneto IRCCS,undefined
[9] Vall d’Hebron Institute of Oncology (VHIO),undefined
[10] Celgene Corporation,undefined
[11] Centre de Lutte Contre le Cancer d’Auvergne,undefined
[12] Texas Oncology-Baylor Charles A. Sammons Center; US Oncology,undefined
[13] Breast Center,undefined
[14] University of Munich,undefined
来源：
Trials | / 17卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Camrelizumab in Combination with Nab-Paclitaxel and Carboplatin versus Nab-Paclitaxel and Carboplatin as Neoadjuvant Therapy for Triple Negative Breast Cancer: A Multicenter, Open-Label, Randomized Controlled Study
    Zhao, Weipeng
    Wang, Xin
    Zhang, Bin
    Shi, Yehui
    Wang, Chen
    Wang, Xu
    Li, Shufen
    Hao, Chunfang
    Lu, Ning
    Jia, Yongsheng
    Zhang, Li
    Zhang, Lan
    Sun, Weixin
    Cao, Xuchen
    Tong, Zhongsheng
    CANCER RESEARCH, 2024, 84 (09)
  • [42] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [43] Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer
    Burris, H
    Yardley, D
    Jones, S
    Houston, G
    Broome, C
    Thompson, D
    Greco, FA
    White, M
    Hainsworth, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1621 - 1629
  • [44] Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2
    Goel, Shom
    Tan, Antoinette R.
    Rugo, Hope S.
    Aftimos, Philippe
    Andric, Zoran
    Beelen, Andrew
    Zhang, Jingshan
    Yi, John S.
    Malik, Rajesh
    O'Shaughnessy, Joyce
    FUTURE ONCOLOGY, 2022, 18 (33) : 3701 - 3711
  • [45] The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
    Lei Yang
    Jing Su
    Wenbo Wang
    Fuxiang Zhou
    World Journal of Surgical Oncology, 21
  • [46] Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)
    Gluck, S.
    Lobo, C.
    Reis, I.
    Lopes, G.
    Carmody, C.
    Tukia, K.
    Hurley, J.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
    Yang, Lei
    Su, Jing
    Wang, Wenbo
    Zhou, Fuxiang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [48] Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma
    Ajjai Alva
    Stephanie Daignault
    David C. Smith
    Maha Hussain
    Investigational New Drugs, 2014, 32 : 188 - 194
  • [49] Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
    Kamata, Ken
    Imai, Hajime
    Matsumoto, Hisakazu
    Yamashita, Yukitaka
    Kato, Takao
    Nishi, Katsuhisa
    Omoto, Shunsuke
    Minaga, Kosuke
    Yamao, Kentaro
    Hyodo, Tomoko
    Im, Sung-Woon
    Hara, Akane
    Yoshikawa, Tomoe
    Ishikawa, Rei
    Okamoto, Ayana
    Yamazaki, Tomohiro
    Nakai, Atsushi
    Ueshima, Kazuomi
    Chiba, Yasutaka
    Takenaka, Mamoru
    Watanabe, Tomohiro
    Kitano, Masayuki
    Kudo, Masatoshi
    JGH OPEN, 2023, 7 (09): : 659 - 666
  • [50] A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
    Fukahori, Masaru
    Miwa, Keisuke
    Murotani, Kenta
    Naito, Yoshiki
    Ushijima, Tomoyuki
    Sakaue, Takahiko
    Tanaka, Toshimitsu
    Nagasu, Sachiko
    Suga, Hideya
    Kakuma, Tatsuyuki
    Okabe, Yoshinobu
    Torimura, Takuji
    MEDICINE, 2021, 100 (20) : E26052
12345